Dong Liu

Dr. Dong Liu

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
XWXinchao Wu
Xinchao Wu
DLDong Liu
Dong Liu
DTDan Tao
Dan Tao
WXWei Xiang
Wei Xiang
XXXingyuan Xiao
Xingyuan Xiao
GJGuosong Jiang
Guosong Jiang
People who develop bladder cancer frequently succumb to the intractable disease. Current treatment strategies are limited presumably due to the underlying molecular complexity and insufficient comprehension. Therefore, exploration of new therapeutic targets in bladder cancer remains necessary. Here, we identify that bromodomain-4 protein (BRD4), an important epigenome reader of bromodomain and extraterminal domain (BET) family member, is a key upstream regulator of enhancer of zeste homologue 2 (EZH2), and represents a novel therapeutic target in bladder cancer. We found that BRD4 was significantly overexpressed in bladder cancer cells and tissues. Inhibition of BRD4 decreased bladder cancer cell proliferation concomitantly with the accumulation of cell apoptosis in vitro and suppressed tumor growth in vivo. We further found that suppression of BRD4 decreased the mRNA and protein levels of EZH2, which was reversed by ectopic expression of C-MYC. In particular, individual silencing of BRD4 using shRNA or the BET inhibitor JQ1 strikingly diminished the recruitment of C-MYC to EZH2 promoter in bladder cancer. Briefly, our research reveals that BRD4 positively regulates EZH2 transcription through upregulation of C-MYC, and is a novel promising target for pharmacologic treatment in transcriptional program intervention against this intractable disease. Mol Cancer Ther; 15(5); 1029–42. ©2016 AACR.

1 January 2022 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
ZYZaoqin Yu
Zaoqin Yu
WLWei Li
Wei Li
XSXiaofang Shangguan
Xiaofang Shangguan
YCYuanxuan Cai
Yuanxuan Cai
QGQianyan Gao
Qianyan Gao
CZChengliang Zhang
Chengliang Zhang
Background: Despite the great signs of progress in cancer pain management in China, the associated pain remains under-treated. Poor knowledge among the medical staff is an important factor contributing to the under-treatment of cancer pain. This study aimed to evaluate the knowledge, practices, and perceived barriers in cancer pain management among the medical staff at oncology units in China. Patients and Methods: A cross-sectional survey was conducted with the medical staff (including physicians, nurses, and pharmacists) at oncology units in tertiary hospitals of China between December 2020 and January 2021. The questionnaire assessed the knowledge, practices, and perceived barriers in cancer pain management. Results: A total of 1262 medical staff responded to the questionnaire; the response rate was 94.2%. Most participants had good knowledge of the three-step analgesic ladder of the World Health Organization (WHO) and the National Comprehensive Cancer Network (NCCN) guidelines for Adult Cancer Pain. Knowledge deficit was prominent in questions on opioid dose titration and rotation and adverse effects of opioids; the correct response rate was less than 40%. Training, work experience in oncology, and education level were significantly related to knowledge of cancer pain management (all P < 0.001). In clinical practice for cancer pain management, approximately 57.2% of medical staff were unfamiliar with opioid dose titration and rotation; only 14.4% treated cancer pain through multidisciplinary collaboration. Poor medication compliance, difficult individualized analgesia protocols, and insufficient multidisciplinary participation were the most frequently perceived barriers by the medical staff for pain management. Conclusion: These findings suggested a further need for integrating recent guidelines to strengthen continued training (especially among juniors and those with low education levels) and patient education to improve the knowledge and clinical practices of cancer pain management among the medical staff in China. Multi-disciplinary management is required for the effective treatment of cancer pain.

13 April 2014 in Lung
Verified
Journal Article
Closed access
PDF file
YFYu-Xuan Feng
Yu-Xuan Feng
DLDong Liu
Dong Liu
MSMing-Li Sun
Ming-Li Sun
XJXin Jiang
Xin Jiang
NSNa Sun
Na Sun
Zhi-Cheng JingZhi-Cheng Jing
Zhi-Cheng Jing

1 July 2017 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
YLYongfang Lei
Yongfang Lei
QCQian Chen
Qian Chen
JCJinglou Chen
Jinglou Chen
DLDong Liu
Dong Liu

5 March 2014 in Chinese Medical Journal
Verified
Journal Article
Open access
DLDong Liu
Dong Liu
ZGZhilong Geng
Zhilong Geng
WZWankun Zhu
Wankun Zhu
HWHuiwen Wang
Huiwen Wang
YCYe Chen
Ye Chen
JLJuan Liang
Juan Liang
Background: A proinflammatory milieu emerging in the lung due to neutrophil accumulation and activation is a key in the pathogenesis of acute lung injury (ALI). 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), one of the terminal products of the cyclooxygenase-2 pathway, is known to be the endogenous ligand of peroxisome proliferator-activated receptor γ (PPAR-γ) with multiple physiological properties. Growing evidence indicates that 15d-PGJ2 has anti-inflammatory, anti-proliferative, cytoprotective and pro-resolving effects. We investigated whether 15d-PGJ2 has a protective effect against endotoxin-induced acute lung injury in rats. Methods: Twenty-four male Wistar rats were randomly assigned into four groups (n=6 per group): sham+vehicle group, sham+15d-PGJ2 group, LPS+vehicle group, and LPS+15d-PGJ2 group. The rats were given either lipopolysaccharide (LPS, 6 mg/kg intravenously) or saline, and pretreated with 15d-PGJ2 (0.3 mg/kg intravenously) or its vehicle (dimethyl sulphoxide) 30 minutes before LPS. Histological alterations, wet/dry weight (W/D) ratio and myeloperoxidase (MPO) activity as well as tumor necrosis factor (TNF)-α and cytokine-induced neutrophil chemoattractant-1 (CINC-1) levels were determined in lung tissues four hours after LPS injection. Immunohistochemical analysis for intercellular adhesion molecule-1 (ICAM-1) expression and Western blotting analysis for nuclear factor (NF)-κB p65 translocation and IκBα protein levels were also studied. Results: 15d-PGJ2 pretreatment significantly attenuated LPS-induced lung injury, and reduced the increased W/D ratio, MPO activity, TNF-α, CINC-1 levels, and ICAM-1 expression in the lung. 15d-PGJ2 also suppressed the nuclear NF-κB p65 translocation and increased cytosolic IκBα levels. Conclusions: 15d-PGJ2 protects against endotoxin-induced acute lung injury, most likely through the reduction of pro-inflammatory protein levels during endotoxemia subsequent to the inhibition of NF-κB activation.

1 February 2019 in Toxicology Letters
Verified
Journal Article
Closed access
YNYa-Lei Ning
Ya-Lei Ning
NYNan Yang
Nan Yang
XCXing Chen
Xing Chen
HTHua-Ke Tian
Hua-Ke Tian
ZZZi-Ai Zhao
Zi-Ai Zhao
YZYuan-Guo Zhou
Yuan-Guo Zhou